• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Pediatrics

Insufficient evidence for screening for major depressive disorder in children

byNicholas WoolfandSai Folmsbee
February 9, 2016
in Pediatrics, Psychiatry
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. From a systematic review, insufficient studies were found examining whether routine screening for pediatric major depressive disorder (MDD) improves depression- or other healthcare-related outcomes.

2. Limited evidence suggests the Patient Health Questionnaire Modified for Adolescents (PHQ-A) and Beck Depression Inventory (BDI) may be the best MDD screening tools for children.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Major depressive disorder (MDD) is prevalent in the pediatric population, with approximately 11% of children aged 8-18 years affected in the last year alone. Moreover, a majority of children suffering from MDD do not receive adequate treatment. A 2009 USPSTF guideline recommended routine screening for MDD in children aged 12 to 18 years in primary care settings, but only if adequate management systems are in place. This review sought to update that guideline by examining available evidence for both screening and treatment of MDD in children. Unfortunately, the review did not find any qualifying trials that directly assessed the benefits and harms of screening children for MDD in primary care settings. Among all MDD screening approaches, the PHQ-A and BDI tools had the highest sensitivity and specificity. In terms of treatment, fluoxetine, fluoxetine with cognitive behavioral therapy (CBT), and collaborative care were associated with the best response rates. This review was limited by strict inclusion criteria (i.e., English language studies related only to MDD screening/treatment in primary care settings), insufficient power to rule out the absence of benefits or harms, and limited generalizability due to heterogeneity in interventions, populations and settings across all included publications. Overall, it is clear that more high-quality studies that examine the utility of pediatric MDD screening in primary care settings are needed.

Click to read the study published today in the Annals of Internal Medicine

Relevant Reading: Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force recommendation statement

RELATED REPORTS

AI health chatbot shows no benefit for perinatal anxiety or depression

American Cancer Society recommends regular PSA-based screening for men at average and higher risk

In-Depth [systematic review]: This review assessed 5 studies on MDD screening accuracy and 4 trials on treatment efficacy via PubMed, Cochrane Library and PsychInfo searches. There were no meta-analyses or retrospective cohort studies that met inclusion criteria. Across all studies that examined screening accuracy, the PHQ-A and BDI tools had the highest sensitivity (range 73%-90%) and specificity (range 81%-94%). Notably, the positive predictive value was low for these screening tools (range 8%-56%), although the negative predictive value was extremely high (range 97%-99.6%). From the trials that assessed treatment approaches for MDD, it was found that fluoxetine (absolute risk difference 25.7%) and fluoxetine with CBT (absolute risk difference 36.2%; p = 0.001) were associated with a significantly higher response compared to placebo. Additionally, a trial examining collaborative care found that it was associated with significant improvement in response rates at 6 and 12 months compared to the control groups (odds ratios 5.2 and 3.9, respectively).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: depressionscreening
Previous Post

Metabolic syndrome severity decreasing among adolescents

Next Post

Patient demographics associated with fewer hospice visits prior to death

RelatedReports

Depression care collage: a calm woman in a linen shirt beside an empty speech bubble, a steaming teacup and a paper sunrise
Artificial Intelligence

AI health chatbot shows no benefit for perinatal anxiety or depression

November 20, 2026
Collage on the PSA blood test: an engraved bladder and prostate, a capped blood tube, a balance scale and a blank calendar
2MM Trial Briefs

American Cancer Society recommends regular PSA-based screening for men at average and higher risk

November 12, 2026
A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
An illustration featuring a heart within a house, with a stethoscope, a scale, and medication, symbolizing heart failure home hospital care.
Artificial Intelligence

An artificial intelligence model demonstrates the potential for improving the efficiency of structural heart disease screening using electrocardiograms

October 21, 2026
Next Post
Patient demographics associated with fewer hospice visits prior to death

Patient demographics associated with fewer hospice visits prior to death

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.